The aim of this study was to retrospectively evaluate toxicity and efficacy of 3 chemoradiation regimens. Methods: Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute. Treatment consisted of radiotherapy to 50 Gy in 25 fractions with concurrent cisplatin and 5-fluorouracil (group A, n ϭ 65), radiotherapy to 50.4 Gy in 28 fractions with concurrent carboplatin and paclitaxel (group B, n ϭ 16) or radiotherapy to 66 Gy in 33 fractions with low-dose cisplatin (group C, n ϭ 13). Toxicity was scored according to Common Terminology Criteria version 3.0. Results: Chemoradiation was planned as neoadjuvant (n ϭ 58) or definitive (n ϭ 36) treatment. Grade 3/4 hematological toxicity occurred in 18 (19%) patients and grade 3 nonhematologic toxicity in 8 (9%) patients. During treatment, 2 patients died (1 from duodenal ulcer bleeding and 1 from stroke). Overall, 81 (86%) patients completed the planned treatment (86%, 94%, and 77% in groups A, B, and C, respectively). Clinically complete or partial response was observed in 28 of 92 (30%) patients (21%, 50%, and 54% in groups A, B, and C, respectively). After clinical and radiologic response evaluation, treatment plan was changed in 14 (15%) patients. A total of 45 patients underwent surgery. Pathologic complete response and downstaging were seen in 12 (27%) and 34 (76%) operated patients, respectively. With a median follow-up of 15 (range, 1-108) months, the 3-year survival was 41% for all patients. Conclusion: With individual treatment planning, different regimens of chemoradiation for esophageal cancer resulted in acceptable rates of toxicity and efficacy.
recently published meta-analysis provided a survival benefit of 13% for neoadjuvant chemoradiation versus surgery alone. 3 The rationale for combining neoadjuvant chemotherapy and radiotherapy is 2-fold: to increase the rate of curative resections by tumor downsizing and downstaging, and to reduce the incidence of micrometastases. One more advantage is the opportunity to evaluate the effectiveness of chemoradiation by histologic examination of the resected esophagus. Alternatively, there is the potential disadvantage of delaying surgery in patients who fail to respond to neoadjuvant treatment, and postoperative morbidity and mortality may increase due to the toxicity of the treatment. 4 It is of interest that the results of a randomized trial comparing chemoradiation alone versus chemoradiation followed by surgery showed that there was no survival benefit for the addition of surgery after chemoradiation. 5 Currently, most of the published studies on (neoadjuvant) chemoradiotherapy are based on a cisplatin/5-fluorouracil (5-FU)regimen. 6 -9 Data on toxic effects and clinical response are limited in most of them. In more recent years, studies on radiotherapy combined with carboplatin and paclitaxel have been published. 10, 11 In these studies, data on toxicity and response are more extensive and show promising results.
The objective of this study was to analyze our results of chemoradiation in the patient-tailored treatment of esophageal cancer. We aimed to evaluate the toxicity and efficacy of 3 different regimens that were applied in the neoadjuvant or definitive setting.
MATERIALS AND METHODS

Study Population
Between January 1997 and December 2007, 812 patients with esophageal cancer were referred for curative or palliative treatment at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital. The group of patients who received concurrent neoadjuvant or definitive chemoradiation (n ϭ 94) was retrospectively studied in detail using clinical and histopathologic data retrieved from hospital records. At the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, neoadjuvant chemoradiotherapy for patients with esophageal cancer started in 1997. Until 2002, this was done incidentally, and thereafter it was used on a regular basis according to a standardized hospital protocol.
Staging and Determination of Treatment Plan
Pretreatment staging procedures included computed tomography (CT) scan of the chest and abdomen, esophageal endoscopic ultrasonography, and external ultrasonography of the neck, with fine needle aspiration on indication. From the year 2004 onwards, positron emission tomography (͓18F͔-FDG-PET) was increasingly used. Bronchoscopy was performed for tumors located at or above the carina, or when tumor extension into the upper airway was suspected. Furthermore, an audiogram and renal function blood tests were obtained to guide the choice for the chemotherapy regimen. If tumor biopsies were performed at an other hospital, tissue specimens were revised. All patients with nonmetastatic disease were discussed at a weekly multidisciplinary meeting by a team of surgeons, gastroenterologists, radiation oncologists, medical oncologists, radiologists, and nuclear medicine physicians, and a treatment plan was determined based on the general condition of the patient, the location of the tumor, and resectability.
Treatment
Operable patients with a resectable tumor (T3N0M0 -1a or T1-3N1M0 -1a) of the thoracic esophagus received neoadjuvant chemoradiation. Definitive chemoradiation was applied when a patient was considered unfit for surgery, when the tumor was considered to be irresectable, or when the tumor was located in the cervical esophagus. In case the length of the esophagus covered by the 95% isodose of a planned dose of 50 Gray (Gy) in 25 fractions exceeded 20 cm, the patient was considered to be ineligible for chemoradiotherapy. Dose modifications were made for toxicity, using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. Three different regimens were used depending on tumor location and contraindications for specific chemotherapeutic agents. Radiotherapy was combined with concurrent cisplatin and 5-FU (group A), carboplatin and paclitaxel (group B), or low-dose cisplatin (group C).
Radiotherapy
In patients with thoracic tumors (group A and B), the clinical target volume consisted of the macroscopic tumor in the esophagus and the periesophageal lymph nodes with a 4-cm margin in craniocaudal direction to take the risk of submucosal spread of the primary tumor into account. Those with cervical tumors (group C) received a similar elective treatment (but usually with smaller cranial margins and elective inclusion of lower neck nodes ͓level II-IV͔) followed by a boost on the macroscopic tumor.
The radiation schedule has been adapted during the study period. After cautious introduction of chemoradiotherapy in 1997 (using a schedule of 36 Gy in 20 fractions), the radiation dose was increased to the currently used 50 Gy in fractions of 2 Gy. As a result, the patients in group A were treated with a dose of 36 to 50 Gy in 18 to 25 fractions. The patients in group B were treated with a dose of 50.4 Gy in 28 fractions and patients in group C received 36 to 50 Gy on elective fields followed by a 16 to 30 Gy boost in fractions of 2 Gy (median dose, 66 Gy). In all 3 groups, 5 fractions per week were given.
The radiation technique and simulation procedure have changed considerably over time. In the first years of the study period, fluoroscopic simulation was used to simulate anteroposterior/posteroanterior fields. Margins for the field borders were usually 5 cm superiorly and inferiorly, and 2 to 2.5 cm laterally on macroscopic tumor. For gastroesophageal junction tumors, a distal (gastric) margin of usually less than 5 cm was added. For all patients, a radiation technique was chosen in such a way that the spinal cord tolerance dose did not exceed 50 Gy in fractions of 2 Gy.
Gradually, CT-based simulation was introduced in the preparation of the treatment planning for the full treatment, and in 2005 intensity modulated radiation was implemented for all patients treated with chemoradiation for esophageal cancer.
Chemotherapy
In group A, radiotherapy was combined with 2 cycles of intravenous cisplatin 75 mg/m 2 (day 1 of the first and last week of chemoradiation) 1 to 2 hours before each fraction of radiotherapy and intravenous 5-FU 800 mg/m 2 (days 1-4 of the first and last week of chemoradiation), which was administered continuously. In case of definitive treatment and if sustained by the patient, 2 additional cycles of cisplatin/5-FU were given without radiotherapy. For patients with hearing loss or diminished renal function (glomer-ular filtration rate Ͻ60 mL/min), cisplatin was considered to be contraindicated. These patients (group B) received a regimen that consisted of carboplatin targeted at an "area under the curve" of 2 and paclitaxel 50 mg/m 2 , administered intravenously on days 1, 8, 15, 22, 29, and 36. The third regimen (group C) combined radiotherapy with low-dose daily cisplatin 6 mg/m 2 over a period of 5 weeks during the first part of radiotherapy treatment, and was given to patients with cancer located in the cervical part of the esophagus, comparable to a regimen used in head and neck cancer. 12 This regimen was given as definitive treatment in all patients.
Restaging and Reevaluation of Treatment Plan
After completion of the chemoradiotherapy, response was assessed by a CT scan of the chest and abdomen and/or by esophagogastroscopy according to Response Evaluation Criteria in Solid Tumors (RECIST). In more recent years, (18F)-FDG-PET was added. If needed, additional diagnostic procedures were performed. The original treatment plan was adjusted on indication, based on the response to chemoradiation and the patients' clinical condition, at a second multidisciplinary team-meeting.
Surgery
Exclusion criteria for esophageal resection were progressive disease during chemoradiation, tumor invasion into neighboring organs, distant metastasis, and insufficient cardiopulmonary reserve. If possible, surgery was planned 5 to 6 weeks after the completion of the administered regimen. Both transhiatal and transthoracic esophageal resections were performed.
Histopathologic Analysis
The sixth edition of the International Union Against Cancer was used for TNM classification and stage grouping. 13 When no macroscopic tumor tissue was seen in the surgical specimen, lesions such as an ulcer or an irregular area covered by mucosa were embedded together with surrounding areas to adequately judge the presence of residual tumor and therapy effects. A resection margin of 1 mm or less was considered microscopically incomplete.
For the purpose of this study, all slides were collected from the archives and reviewed by an experienced pathologist (M.F.v.V.) to assess the degree of histomorphologic response. She was blinded to the clinical features and response rates. The response was classified into 5 categories as described by Mandard et al 14 : Tumor Regression Grade (TRG) 1: no residual cancer (complete regression); TRG 2: rare residual cancer cells; TRG 3: fibrosis outgrowing residual cancer; TRG 4: residual cancer outgrowing fibrosis; TRG 5: absence of regressive change. Furthermore, for patients with TRG 2 to 5, the pathologic TN stage was reevaluated to assess the possible downstaging effect of chemoradiation. The pretreatment (clinical) stage was compared with the postsurgical (pathologic) stage. Downstaging was defined as either a reduction in the T descriptor, the N descriptor, or both.
Follow-up
For all patients, follow-up visits were performed every 3 months during the first 2 years and every 6 months thereafter. Radiologic examinations were performed only on indication. Follow-up data were collected until death or December 31, 2008.
Statistical Analysis
All data were analyzed using SPSS version 15.0. Survival time was calculated from the first day of chemoradiation to the date of death or last follow-up by means of a life-table analysis. Overall survival calculations included in-hospital mortality. In-hospital mortality was defined as death occurring after surgery within the hospital setting. Overall survival was estimated using the Kaplan-Meier method.
RESULTS
Patient Characteristics
Ninety-four patients were treated with concurrent chemoradiation as neoadjuvant or definitive treatment. Characteristics of these patients are listed in Table 1 . Of all patients, 73% had stage III-IVa disease. Histology included mostly adenocarcinoma (n ϭ 46) and squamous cell carcinoma (n ϭ 43). In 58 patients (51 patients in group A and 7 patients in group B) surgery was planned following chemoradiation. In the remaining 36 patients, chemoradiation was planned as definitive treatment (14 patients in group A, 9 patients in group B, and all 13 patients in group C). Detailed information on radiotherapy is provided in Table 2 .
Toxicity of Chemoradiotherapy
Hematological toxicities are given in Table 3 . Grade 4 hematological toxicity occurred only in group A (n ϭ 5), and grade 3 hematological toxicity was seen in 13 patients. Blood transfusions were only required in a patient with duodenal ulcer bleeding. Nonhematologic toxicities are listed in Table 4 . They consisted mainly of nausea, vomiting, and esophagitis. Grade 4 nonhematologic toxicity did not occur, and grade 3 nonhematologic toxicity was experienced by 6 patients in group A and by 2 patients in group C. In total, 24 (25%) patients experienced grade 3 or 4 (non-) hematological toxicity during treatment (25%, 38%, and 15% in group A, B, and C, respectively). In our study population, there were no patients with signs of radiation myelitis. Twenty-nine (31%) patients required nutritional support during chemoradiotherapy.
Seven patients (5 patients in group A, 1 patient in group B, and 1 patient in group C) had to stop their chemotherapy regimen prematurely, all because of grade 3 or 4 toxicity. One patient (group C) did not receive the last fraction of radiation because of respiratory insufficiency due to bilateral vocal cord paralysis. In 5 patients, both chemo-and radiotherapy were discontinued because the disease progressed to distant sites (1 patient in group A and 1 in group C), because the patient died during treatment (one patient in group A from a duodenal ulcer bleeding and an other patient in group A from a cerebral infarction), or upon patients request (1 patient in group A). Eighty-one (86%) patients completed the chemoradiation as planned: 56 (86%) in group A, 15 (94%) in group B, and 10 (77%) patients in group C.
Response to Chemoradiotherapy
In 2 of 94 patients, response evaluation was not possible because they had died during chemoradiation. Response evaluation was done after a median of 21 (range, 3-84) days following the last radiotherapy session. Clinically complete or partial response was observed in 28 of 92 (30%) patients (21%, 50%, and 54% in groups A, B, and C, respectively), and progression of disease in 6 of 92 (7%) patients. On the basis of these response evaluation results, in Group A, 5-fluorouracil/cisplatin-based regimen; Group B, carboplatin/paclitaxelbased regimen; Group C, low-dose cisplatin-based regimen.
Additional information on radiation techniques: Group A: In all patients treated with a dose of 46 Gy or less (n ϭ 26), only parallel opposing fields were used. Patients treated with a dose of 50 Gy were either treated with parallel opposed fields to a dose of 40 Gy in 20 fractions followed by a boost (same field length) with 3 dimensional (3D) planning (n ϭ 12), or with 3D planning or intensity modulated radiation therapy (IMRT) for the whole radiation series (n ϭ 27).
Group B: all patients were treated using 3D planning or IMRT for the whole radiation series.
Group C: Until 2005, patients were treated on the macroscopic tumor with broad margins considered to be at risk using parallel opposing fields up to 46 Gy in 23 fractions followed by a boost on the macroscopic tumor with limited margins using 3D planning. As of 2005, IMRT was used for the entire treatment; elective fields were treated up to 46 Gy in 23 fractions followed by a boost.
*The median radiation dose in the group treated with a dose between 36 and 50 Gy was 44 Gy. combination with the reevaluation of the patient's clinical condition, the original treatment plan was changed in 14 of 92 (15%) patients. In 13 patients, the neoadjuvant treatment changed into definitive treatment (10 patients in group A and 3 patients in group B). Reasons for this change were clinical deterioration/severe toxicity (n ϭ 6), progressive disease (n ϭ 4), or patient's own request (n ϭ 3). One patient underwent surgery because of an excellent response to chemoradiation, although it had initially been planned as definitive treatment because of suspected growth into the aorta (group A).
Surgical Results
The median time between the completion of chemoradiation and surgery was 39 days (range, 21-73 days). Of the 45 patients who were operated, 4 patients did not undergo resection because of hepatic and/or peritoneal tumor dissemination. Postoperative mortality was 2%; one cardiovascularly compromised patient died of myocardial infarction 3 days after surgery (group A). In 25 (61%) patients, the postoperative course was uneventful.
Pathologic Results
In 12 of 45 operated patients, no residual tumor in the resected esophagus and no regional lymph node metastases were found, corresponding to a pathologic complete response rate of 27% (11 of 41 ͓27%͔ patients in group A and 1 of 4 ͓25%͔ patients in group B). A microscopically radical (R0) resection was obtained in all 41 patients who underwent a resection. Upon histopathologic review, tumor regression was scored as follows in 41 resected patients: TRG 1 in 12 (29%) patients, TRG 2 in 13 (32%) patients, TRG 3 in 10 (24%) patients, TRG 4 in 5 (12%) patients, and TRG 5 in 1 (2%) patient. Correlation between clinical response (RECIST) and pathologic response (TRG) is shown in Table 5 . It shows that clinical response had an accuracy of only 15% to identify histopathologic response.
Downstaging was observed in 34 (76%) patients. Clinical and pathologic stages for 41 resected patients are demonstrated in Table  6 . Downstaging of T alone occurred in 12 (29%), N alone in 3 (7%), and both descriptors in 19 (46%) patients.
Survival
Median follow-up time for all patients was 15 months (range, 1-108 months). Overall survival was 70% at 1 year and 41% at 3 years. The 1-and 3-year survival rates were 65% and 41% in group A, 88% and 55% in group B, and 76% and 19% in group C. In the group of patients who underwent neoadjuvant chemoradiation followed by surgery (n ϭ 45), median overall survival was 44 (95% CI: 28 -60) months and 1-and 3-year survival were 79% and 61%, respectively. In group A, 1-and 3-year survival were 77% and 56% after surgery (n ϭ 41). Tumor regression grade was not statistically significant correlated with survival (P ϭ 0.481; Fig. 1 ). Median overall survival for patients with complete tumor regression (TRG 1) had not yet been reached, and 1-and 3-year survival rates were 83% and 72%, respectively. Among the 41 resected patients, 19 (46%) developed recurrent disease. Recurrence was only locore-gional in 2 patients, only distant in 13 patients, and both locoregional and distant in 4 patients.
In the group of patients who received chemoradiation as definitive treatment (n ϭ 49), median overall survival was 15 (95% CI: 11-19) months, and 1-and 3-year survival were 63% and 24%, respectively.
DISCUSSION
In this study, we analyzed the toxicity and efficacy of 3 different regimens of concurrent chemoradiation given as neoadjuvant or definitive treatment to patients with esophageal cancer. Our study results indicated that (1) acceptable rates of toxicity and efficacy could be achieved in selected patients, (2) different regimens may be used depending on tumor location and contraindications for specific chemotherapeutic agents, (3) reevaluation of the patient's clinical condition and extent of disease after chemoradiation altered the original treatment plan in a considerable number of patients, and (4) pathologic assessment of tumor regression identified a subgroup of patients with a good prognosis.
The standard treatment for nonmetastatic, locally advanced esophageal cancer is subject to discussion. The introduction of neoadjuvant chemoradiation has resulted in conflicting results. 3, 8, [15] [16] [17] Alternatively, the additional effect of surgery after chemoradiation for potentially resectable disease has also been questioned. 5, 18 Most of the published studies on neoadjuvant chemoradiation are based on the classic cisplatin/5-FU regimen, with limited data on toxic effects and clinical response. In our study, this 1  3  cT3N1  10  5  1  3  1  2  4  2 6  cT4N1  --1  ----1  Total  12  9  6  4  1  4  5  4 1 regimen was well tolerated. Of the 65 patients who were treated with this regimen, 86% completed the planned preoperative regimen. Grade 3 or 4 toxicity-mainly leucopenia, neutropenia, and nausea-occurred in 25% of patients. A pathologic complete response was found in 27% of patients who underwent surgery after chemoradiation with cisplatin/5-FU, comparing favorably with 16% to 26% in previous reports. 6 -9 Furthermore, 3-year survival for the operated patients was 56%, which is favorable compared with the range of 19% to 38% reported in the literature. 6 -9 It emphasizes that with strict selection and response assessment following neoadjuvant treatment, good survival results for this potentially fatal disease can be achieved. In case of diminished renal function or hearing loss, an alternative regimen consisting of paclitaxel and carboplatin with concurrent radiotherapy was administered. The efficacy of this combined treatment has been shown in patients with advanced non-small cell lung cancer. 19 Reported toxicity rates were within normal ranges. These results have led to the implementation of a comparable regimen in the treatment of esophageal cancer. 10, 11 In our small group of 16 patients, severe toxicity consisted exclusively of grade 3 hematological toxicity in 38%. Severe nonhematologic toxicity did not occur. This led to a completion of treatment in 94%, which is in line with the 88% to 98% mentioned in the literature. 10, 11 However, both the total dose of chemotherapy and radiotherapy were higher in our study than in previously mentioned reports. 10, 11 Clinical response evaluation showed a complete or partial response in 50% of patients. Six patients were considered fit enough for esophagectomy, but 2 patients refused surgery. Since only 4 patients eventually underwent surgery in this group, no conclusions can be drawn from their surgical and pathologic results. The 1-and 3-year survival rates for all 16 patients were 88% and 55%, in line with the results from an other study, in which this regimen was also given both as neoadjuvant and definitive treatment. 11 The results of a Dutch multicenter phase III study comparing the combination of paclitaxel and carboplatin with concurrent radiotherapy in the neoadjuvant setting to surgery alone will give further insight in its potential value. 20 Radiotherapy in combination with concurrent low-dose cisplatin is commonly used in patients with advanced head and neck cancer. A meta-analysis in head and neck cancer patients has shown that concurrent chemoradiation leads to improved locoregional control and survival compared with radiation alone. 21 At our institute, Hoebers et al studied a regimen of 46 Gy in 23 fractions to the primary tumor and bilateral neck, followed by a boost of 24 Gy in 12 fractions. 22 Cisplatin was given to 47 patients at a dose of 6 mg/m 2 daily, for a total number of 20 doses. The results of this study were in line with the literature. 21 A comparable regimen is used in our institute as definitive therapy for patients with cancer located in the cervical part of the esophagus. Grade 3 toxicity was rare (15%) and grade 4 did not occur. The 1-and 3-year survival rates were 76% and 19%, respectively. Although this group is small, results justify the administration of this regimen to this selected group of patients for whom surgery would usually include a larynx-pharynx extirpation.
Many studies have been published supporting either neoadjuvant or definitive chemoradiation. In our hospital, the choice for one strategy or the other is part of individual treatment planning. And importantly, this decision is reevaluated following chemoradiation. In this study, 14 (15%) patients had a change of treatment plan, because of tumor progression, deterioration of patient's clinical condition, patient's own request or, alternatively, and excellent response to chemoradiation. Each individual treatment plan should be adjusted and readjusted according to changes in the patient's clinical condition and extent of disease, thereby reducing the risk of treatment failures.
In the group of patients, who underwent surgery, we found no significant association between tumor regression grade and survival. report on the Mandard tumor regression grade did find a significant difference. 14 In our study, 35 of 41 (85%) patients had a good response, defined as TRG 1 to 3, versus 58 of 93 (62%) patients in Mandard's study. The higher percentage of a good response in our series may be because of a higher administered dose of chemotherapy and radiotherapy. Our results confirm that patients with complete tumor regression (TRG 1) have a good prognosis (1-and 3-year survival were 83% and 72%, respectively). Clinically, it remains difficult to discriminate between tissue reactions after chemoradiation (inflammation, necrosis, fibrosis) and vital residual tumor. Therefore, patients with apparently complete response by radiologic or endoscopic measures should not be denied surgical resection. PET is reported to identify histopathologic response with a superior accuracy compared with CT and esophageal endoscopic ultrasonography. 26 In our study, PET was performed in only 7 of 41 resected patients. This may explain the poor diagnostic accuracy of clinical response evaluation in the present series. Downstaging was reached in 76% of the operated patients. However, this percentage is biased by the selection of patients for surgery. Still, it apparently underestimates the actual response rate to chemoradiation since TRG 1 to 3 was 85%. Pathologic assessment of T and N status fails to adequately indicate the effect of neoadjuvant chemoradiation. Ideally, tumor regression grade should be added to describe the end result of neoadjuvant treatment.
The merits of this study include the detailed scoring of both hematologic and nonhematologic toxicities, which is often omitted in studies on chemoradiotherapy for esophageal cancer. Second, the study was strengthened by the assessment of the pathologic response according to Mandard. In combination with the clinical response assessment according to RECIST, the accuracy of response evaluation could be calculated. Third, frequent evaluation, as performed at our institute, altered the original treatment plan in a considerable number of patients (15%) and proved its important role in individual treatment planning. Several limitations of the study should also be noted. The major limitation of this study was its retrospective design. Furthermore, each treatment group was relatively small, and median follow-up time was relatively short.
In conclusion, the results of our study show that different regimens of concurrent chemoradiation in selected patients with locally advanced esophageal cancer can be administered and can lead to acceptable results. Both in the neoadjuvant setting and as definitive treatment modality, the role of chemoradiotherapy in the treatment of esophageal cancer is increasing. Therefore, efforts to minimize toxicity and maximize efficacy are increasingly important. Key elements for such efforts are selection, patient-tailored treatment, and frequent evaluation; "one size fits all" is not applicable. The use of biologic markers may help to further individualize choices of chemoradiotherapeutic regimens.
